Supernus Pharmaceuticals Inc expected to post earnings of 39 cents a share - Earnings Preview

Supernus Pharmaceuticals

03/08/2024 24:24

* Supernus Pharmaceuticals Inc  SUPN.OQ   SUPN.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 6 for the period ending January 1 0001
    * The Rockville Maryland-based  company is expected to
report a
9.8% increase in revenue to $148.852 million from $135.56
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Supernus Pharmaceuticals
Inc
is for earnings of 39 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $40.50​, above​ its last closing price
of $28.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.38        0.38       0.26      Missed  -31
 Dec. 31 2024  0.50        0.55       0.89      Beat    60.8
 Sep. 30 2023  0.07        0.08       0.24      Beat    200​
 Jun. 30 2023  -0.23       0.07       -0.02     Missed  -130.8
 ​​Mar.        0.13        0.17       0.29      Beat    70.6
 31 2023                                                
 Dec. 31 2022  0.70        0.68       0.43      Missed  -36.8​
 Sep. 30 2022  0.44        0.36       0.03      Missed  -91.6
 Jun. 30 2022  0.33        0.29       0.14      Missed  -51.7
 This summary was machine generated August 2 at 23:24 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)